Literature DB >> 16235180

Conjugate pneumococcal vaccine in HIV-infected Ugandans and the effect of past receipt of polysaccharide vaccine.

George Miiro1, Helena Kayhty, Christine Watera, Helen Tolmie, James A G Whitworth, Charles F Gilks, Neil French.   

Abstract

We investigated the immunogenicity of a 7-valent conjugate pneumococcal vaccine (CPV) in human immunodeficiency virus-infected Ugandan adults and measured the effect of past pneumococcal polysaccharide vaccine (PPV) receipt given as part of a controlled trial. Two doses of CPV, 4 weeks apart, were given to 54 past PPV recipients and 55 past placebo recipients (84% female; median CD4 cell count, 251 cells/ microL [range, 1-936 cells/ microL]). Postvaccination anticapsular immunoglobulin G (IgG) concentrations were directly correlated with CD4 cell count (P < .01 for all serotypes). There were significant increases in anticapsular IgG concentrations for all serotypes after the first dose (P < .01) and for all serotypes except 14 and 9V after the second dose. Past receipt of PPV did not affect vaccine response.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16235180     DOI: 10.1086/497144

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  15 in total

1.  Pneumococcal capsular polysaccharide vaccine-mediated protection against serotype 3 Streptococcus pneumoniae in immunodeficient mice.

Authors:  Haijun Tian; Avi Groner; Marianne Boes; Liise-anne Pirofski
Journal:  Infect Immun       Date:  2007-01-12       Impact factor: 3.441

2.  T cell responses of HIV-infected children after administration of inactivated or live attenuated influenza vaccines.

Authors:  Adriana Weinberg; Lin-Ye Song; Terence Fenton; Sharon A Nachman; Jennifer S Read; Julie Patterson-Bartlett; Myron J Levin
Journal:  AIDS Res Hum Retroviruses       Date:  2010-01       Impact factor: 2.205

3.  A trial of a 7-valent pneumococcal conjugate vaccine in HIV-infected adults.

Authors:  Neil French; Stephen B Gordon; Thandie Mwalukomo; Sarah A White; Gershom Mwafulirwa; Herbert Longwe; Martin Mwaiponya; Eduard E Zijlstra; Malcolm E Molyneux; Charles F Gilks
Journal:  Malawi Med J       Date:  2016-09       Impact factor: 0.875

4.  A trial of a 7-valent pneumococcal conjugate vaccine in HIV-infected adults.

Authors:  Neil French; Stephen B Gordon; Thandie Mwalukomo; Sarah A White; Gershom Mwafulirwa; Herbert Longwe; Martin Mwaiponya; Eduard E Zijlstra; Malcolm E Molyneux; Charles F Gilks
Journal:  N Engl J Med       Date:  2010-03-04       Impact factor: 91.245

5.  Association of time since pneumococcal polysaccharide vaccine receipt and CD4 count with antibody response to the 13-valent pneumococcal conjugate vaccine in HIV-infected adults.

Authors:  Alexandria E-B Rossheim; Anna Marie P Young; Julia Siik; Tina D Cunningham; Stephanie B Troy
Journal:  Hum Vaccin Immunother       Date:  2016-05-12       Impact factor: 3.452

6.  A randomized clinical trial comparing revaccination with pneumococcal conjugate vaccine to polysaccharide vaccine among HIV-infected adults.

Authors:  Nancy F Crum-Cianflone; Katherine Huppler Hullsiek; Mollie Roediger; Anuradha Ganesan; Sugat Patel; Michael L Landrum; Amy Weintrob; Brian K Agan; Sheila Medina; Jeremy Rahkola; Braden R Hale; Edward N Janoff
Journal:  J Infect Dis       Date:  2010-10-01       Impact factor: 5.226

Review 7.  Pneumococcal vaccination among HIV-infected adult patients in the era of combination antiretroviral therapy.

Authors:  Kuan-Yeh Lee; Mao-Song Tsai; Kuang-Che Kuo; Jen-Chih Tsai; Hsin-Yun Sun; Aristine C Cheng; Sui-Yuan Chang; Chen-Hsiang Lee; Chien-Ching Hung
Journal:  Hum Vaccin Immunother       Date:  2014       Impact factor: 3.452

8.  Cross-sectional study of nasopharyngeal carriage of Streptococcus pneumoniae in human immunodeficiency virus-infected adults in the conjugate vaccine era.

Authors:  Chinwendu Onwubiko; Edwin Swiatlo; Larry S McDaniel
Journal:  J Clin Microbiol       Date:  2008-09-24       Impact factor: 5.948

9.  Clostridium difficile in a HIV-infected cohort: incidence, risk factors, and clinical outcomes.

Authors:  Charles F Haines; Richard D Moore; John G Bartlett; Cynthia L Sears; Sara E Cosgrove; Karen Carroll; Kelly A Gebo
Journal:  AIDS       Date:  2013-11-13       Impact factor: 4.177

10.  Pneumococcal conjugate vaccine is immunogenic in lung fluid of HIV-infected and immunocompetent adults.

Authors:  Stephen B Gordon; Helena Kayhty; Malcolm E Molyneux; Raili Haikala; Anu Nurkka; Janelisa Musaya; Eduard E Zijlstra; Dennis Lindell; Neil French
Journal:  J Allergy Clin Immunol       Date:  2007-06-04       Impact factor: 10.793

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.